Treatment of total exudative retinal detachment due to central retinal vein occlusion by intravitreal bevacizumab in a patient with p-ANCA vasculitis.
OBJECTIVE
To report on the use of intravitreal bevacizumab (an anti-vascular endothelial growth factor [VEGF] monoclonal antibody) as treatment of diffuse exudative retinal detachment due to ischemic central retinal vein occlusion (CRVO).


METHODS
Interventional case report.


METHODS
A 27-year old woman on peritoneal dialysis because of end stage renal failure (ESRF) due to perinuclear antineutrophil cytoplasmic antibody (p-ANCA) associated vasculitis presented with acute unilateral blurred vision. Visual acuity (VA) rapidly deteriorated. Examination revealed the development of total bullous exudative retinal detachment following ischemic CRVO.


METHODS
Two intravitreal injections of bevacizumab (2.5 mg/0.1ml) were administered followed by panretinal laser photocoagulation.


METHODS
VA, retinal detachment, and changes in macular edema.


RESULTS
Prompt significant resolution of exudative retinal detachment with a corresponding gradual improvement of VA from light perception to finger counting. At follow-up examination after 8-months, the retina remained attached.


CONCLUSIONS
Intravitreal bevacizumab proved to be a useful treatment modality in diffuse exudative retinal detachment due to CRVO.
Ferencz
Joseph R
JR
Department of Ophthalmology, Meir Medical Center, Kfar Saba, Israel. j@ferencz.info
Rosen
Eli
E
Tam
Guy
G
Gilady
Gila
G
Rubowich
Alexander
A
Assia
Ehud I
EI
Korzets
Ze'ev
Z